Table 3.

Factors associated with presence of tubular macrovacuoles on biopsy at 3 mo among IVIg-treated patients

ParametersMacrovacuoles at 3 moP
Yes (n = 17)No (n = 10)
Pretransplantation parameters
    donor age (yr; mean ± SD)51.4 ± 11.238 ± 16.2<0.003
    cold ischemia time (h; mean ± SD)25.6 ± 9.226.0 ± 6.7NS
    iodinated contrast agent before transplantation (n [%])5/9 (55.6)6/10 (60.0)NS
    female recipient (n [%])8 (47)5 (50)NS
Posttransplantation parameters
    recipient age (yr; mean ± SD)44.6 ± 11.245.7 ± 9.9NS
    recipient weight (kg; mean ± SD)60.7 ± 11.955.5 ± 7.4NS
    body surface area (m2; mean ± SD)1.7 ± 0.21.6 ± 0.1NS
    IVIg cumulative dosage (g; mean ± SD)373 ± 170330 ± 145NS
    delayed graft function (n [%])12 (70.6)6 (60.0)NS
    posttransplantation plasma exchange therapy (mean ± SD)7.6 ± 9.23.5 ± 6.1NS
    acute rejection at 3 mo (n [%])5 (29.4)2 (20.0)NS
    cyclosporine at 3 mo (n [%])3 (17.6)1 (10.0)NS
    cyclosporine C2 at 3 mo (ng/ml; mean ± SD)1296 ± 148686NS
    tacrolimus at 3 mo (n [%])14 (82.4)9 (90.0)NS
    tacrolimus C0 at 3 mo (ng/ml; mean ± SD)10.7 ± 3.111.3 ± 3.3NS